Medico Remedies Limited (MEDICO) — Multibagger Analysis

1. Ramp-Aware Impact Math

• Revenue Estimation: The company reported a net profit of ’4.39 crore for H1 FY26 (ended Sep 30, 2025). Given historical net profit margins (NPM) of ~7%, we estimate H1 FY26 revenue at ~’62.7 crore, translating to an annualized TTM revenue of ~’120-125 crore.
• Order Sizing: The ’73.23 crore order from UP Medical Supplies Corp represents ~61% of estimated TTM revenue. This is a highly material order.
• Execution Timeline: The order is mandated to be completed by October 31, 2026 (~9.3 months). Assuming immediate commencement, this translates to an annualized execution rate of ~’94 crore. However, factoring in typical government supply-chain bottlenecks, we model a realistic Year-1 execution of 80-85% of the order value (~’60 crore), yielding a Year-1 revenue uplift of ~50%.
• Margin & EPS Impact: Government tenders are highly competitive and typically yield lower margins than Medico's core export business (95% of sales). We model a conservative 6% NPM on this order (vs. 7% normal NPM). This yields an incremental PAT of ~’4.39 crore over the execution period. Compared to the annualized H1 FY26 PAT of ~’8.8 crore, this represents a steady-state EPS uplift of ~45-50%, assuming no equity dilution.

2. Industry Capital Intensity & Growth

• Capital Intensity: Medium. While formulation manufacturing requires moderate capex, the working capital intensity is extremely high, especially for government contracts where payment cycles can exceed 180-200 days.
• Industry CAGR: The Indian pharmaceutical industry is expected to grow at 6-8% YoY in FY25, with pharmerging markets growing slightly faster. Medico's target growth rate of 11% is achievable but dependent on successful capacity expansion (beta-lactam facility).

3. Multibagger Quality Assessment

• Positives: Strong historical ROCE of 21.0% and low leverage (D/E of 0.24 on ’15 crore debt vs. ’63 crore net worth) provide a solid foundation. Promoter holding is stable at 61.4%.
• Negatives: High client concentration (top 5 customers at 56% of revenue) and lack of pricing power are structural concerns. The complete lack of recent quarterly tables in the structured data is a major transparency gap.

4. Scenario Analysis

• Base Case (40% Upside): Order is executed with minor delays by late 2026. Working capital is managed via short-term debt without severely hurting liquidity. NPM holds at 6%.
• Bull Case (75% Upside): Flawless execution by October 2026. Prompt payments from the UP government prevent a working capital crunch. Operating leverage from the new beta-lactam facility kicks in, pushing NPM to 8%.
• Bear Case (-25% Downside): Severe payment delays (>250 days GCA) lead to a cash crunch, forcing high-interest debt accumulation. Quality compliance issues lead to penalties or order cancellation.

5. Verdict Rationale

While the order is highly material and transformational in terms of scale, the high working capital risks associated with state government contracts, combined with significant data gaps (missing quarterly tables), prevent a 'STRONG_CANDIDATE' rating. It is classified as a 'POSSIBLE' multibagger, contingent on clean execution and working capital management.